Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment Robin M. L. MurrayPaula Pitt Report Pages: 91 - 95
Sequential endocrine therapy and chemotherapy in metastatic breast cancer: Effects on survival Andrea ManniOlof H. PearsonBahauddin M. Arafah US-Japan Conference on Chemoendocrine Therapy Pages: 97 - 103
Chemoendocrine therapy in advanced breast cancer David T. KiangB. J. Kennedy US-Japan Conference on Chemoendocrine Therapy Pages: 105 - 109
A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer Douglass C. TormeyRebecca GelmanGeoffrey Falkson US-Japan Conference on Chemoendocrine Therapy Pages: 111 - 119
Combined chemo-hormonal therapy in breast cancer: A hypothesis C. Kent Osborne US-Japan Conference on Chemoendocrine Therapy Pages: 121 - 123
Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer Masaru IzuoYuichi IinoKeiichi Endo US-Japan Conference on Chemoendocrine Therapy Pages: 125 - 130
Adjuvant therapy for stage II, estrogen receptor negative breast cancer William A. Knight IIIGary M. ClarkWilliam L. McGuire US-Japan Conference on Chemoendocrine Therapy Pages: 131 - 134
Hormone receptors and obesity in Japanese women with breast cancer Keijiro KunoAtsuo FukamiFujio Kasumi US-Japan Conference on Chemoendocrine Therapy Pages: 135 - 139
Potential and problems with growth of breast cancer in a human tumor cloning system Daniel D. Von HoffJohn Sandbachthe South Central Texas Human Tumor Cloning Group US-Japan Conference on Chemoendocrine Therapy Pages: 141 - 148
